Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. body says gene therapy may be more cost effective for spinal muscular atrophy

Biogen Inc.’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said.

Read More »

FDA Approves Herceptin Biosimilar Herzuma

Celltrion Inc. and Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration approved Herzuma (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to Herceptin (trastuzumab).

Read More »

Senate Democrats introduce bill to allow government to block drug price rises

Four Democratic U.S. senators introduced a bill that would allow the government to block drug price increases that are unjustified.

Read More »

Healthcare Agency Roundtable 2018

Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.

Read More »

Ad-ventures in Marketing XI

For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.

Read More »

U.S. healthcare spending growth slows for second year in a row

Healthcare spending growth in the United States slowed for the second year in a row in 2017, mainly due to slower spending growth for hospital care, physician and clinical services as well as retail prescription drugs, according to a report from the U.S. Centers for Medicare and Medicaid Services.

Read More »

Mylan to recall all batches of blood pressure medicine valsartan in U.S.

Mylan NV is issuing a nationwide voluntary recall of all lots of the company’s blood pressure medicine valsartan.

Read More »

J&J-AbbVie cancer drug Imbruvica succeeds in late-stage trial

Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.

Read More »

Johnson & Johnson’s multiple myeloma drug reduces risk of death in late-stage study

Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.

Read More »

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom